Literature DB >> 24051694

Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis.

Ta-Chiang Liu1, Neeta Vachharajani2, William C Chapman2, Elizabeth M Brunt1.   

Abstract

The majority of hepatocellular carcinomas arise in background chronic liver disease, particularly cirrhosis. The pathogenesis of noncirrhotic hepatocellular carcinomas remains unclear. While malignant transformation reportedly occurs in <15% of hepatocellular adenoma, the prevalence of noncirrhotic hepatocellular carcinomas arising from a pre-existing adenoma is a challenge to study. Cirrhotic hepatocellular carcinoma and hepatocellular adenoma may be subclassified by molecular pathways, but little is known in noncirrhotic hepatocellular carcinoma. We aim to delineate clinical, morphologic and immunohistochemical features of noncirrhotic hepatocellular carcinoma to evaluate for possible derivation from hepatocellular adenoma. We evaluated the clinicopathologic features of 74 noncirrhotic hepatocellular carcinomas from 72 patients for underlying clinical conditions and immunohistochemical markers known to be associated with hepatocellular adenoma. Men were more commonly affected (59%); however, in the <50-year-old group, women predominated (8:1). The age range was wide: 18-83 years; median-64 years. Underlying liver diseases were identified in only 7%; however, 25% had diabetes mellitus, 69% were overweight or obese and 58% had metabolic syndrome. Only 50% of the noncirrhotic hepatocellular carcinoma were encapsulated. As published in hepatocellular adenoma, multifocality and larger tumor size were more common in liver fatty acid-binding protein-negative noncirrhotic hepatocellular carcinoma. Beta-catenin nuclear positivity was uncommon (5%), and was restricted to hepatocellular carcinomas in older men. Serum amyloid A positivity was not restricted to any subtype. In summary, we present the largest series to date examining noncirrhotic hepatocellular carcinoma. We evaluated these with current hepatocellular adenoma subclassification markers for possible associations. Thirty percent of the 74 noncirrhotic hepatocellular carcinoma had some clinical, morphological or immunophenotypical associations currently described in hepatocellular adenoma. Our data also confirm the association of noncirrhotic hepatocellular carcinoma in middle-aged to elderly men, an association with metabolic syndrome, and, as with hepatocellular adenoma, that women predominated in the noncirrhotic hepatocellular carcinoma subjects <50 years of age.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24051694      PMCID: PMC5861497          DOI: 10.1038/modpathol.2013.148

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  38 in total

1.  Two decades of advances in hepatocellular carcinoma research.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

2.  Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival.

Authors:  Eric Dupont-Bierre; Philippe Compagnon; Jean-Luc Raoul; Gabriel Fayet; Anne-Sophie de Lajarte-Thirouard; Karim Boudjema
Journal:  J Am Coll Surg       Date:  2005-09-30       Impact factor: 6.113

3.  The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.

Authors:  Naoko Yamauchi; Akira Watanabe; Michiyo Hishinuma; Ken-Ichi Ohashi; Yutaka Midorikawa; Yasuyuki Morishita; Toshiro Niki; Junji Shibahara; Masaya Mori; Masatoshi Makuuchi; Yoshitaka Hippo; Tatsuhiko Kodama; Hiroko Iwanari; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Mod Pathol       Date:  2005-12       Impact factor: 7.842

4.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

5.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.

Authors:  Luca Di Tommaso; Giada Franchi; Young Nyun Park; Barbara Fiamengo; Annarita Destro; Emanuela Morenghi; Marco Montorsi; Guido Torzilli; Maurizio Tommasini; Luigi Terracciano; Luigi Tornillo; Raffaella Vecchione; Massimo Roncalli
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

6.  Population-based risk factors and resource utilization for HCC: US perspective.

Authors:  A Sanyal; A Poklepovic; E Moyneur; V Barghout
Journal:  Curr Med Res Opin       Date:  2010-09       Impact factor: 2.580

Review 7.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

8.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.

Authors:  Camilla Pilati; Mohamed Amessou; Michel P Bihl; Charles Balabaud; Jeanne Tran Van Nhieu; Valérie Paradis; Jean Charles Nault; Tina Izard; Paulette Bioulac-Sage; Gabrielle Couchy; Karine Poussin; Jessica Zucman-Rossi
Journal:  J Exp Med       Date:  2011-06-20       Impact factor: 14.307

View more
  7 in total

Review 1.  Malignant transformation of hepatocellular adenoma.

Authors:  Christine Sempoux; Charles Balabaud; Paulette Bioulac-Sage
Journal:  Hepat Oncol       Date:  2014-12-11

Review 2.  Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?

Authors:  Giovanni Targher; Maurizio Rossini; Amedeo Lonardo
Journal:  Endocrine       Date:  2015-05-30       Impact factor: 3.633

3.  Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions.

Authors:  Xi Chen; Masahiro Yamamoto; Kiyonaga Fujii; Yasuharu Nagahama; Takako Ooshio; Bing Xin; Yoko Okada; Hiroyuki Furukawa; Yuji Nishikawa
Journal:  Cancer Sci       Date:  2015-06-25       Impact factor: 6.716

4.  Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model.

Authors:  Sarah Walker; Miriam Wankell; Vikki Ho; Rose White; Nikita Deo; Carol Devine; Brittany Dewdney; Prithi Bhathal; Olivier Govaere; Tania Roskams; Liang Qiao; Jacob George; Lionel Hebbard
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

5.  Malignant transformation of hepatocellular adenoma.

Authors:  Céline Julien; Brigitte Le Bail; Laurence Chiche; Charles Balabaud; Paulette Bioulac-Sage
Journal:  JHEP Rep       Date:  2022-01-07

6.  Hepatocellular Carcinoma in a Free-Ranging Three-Toed Sloth (Bradypus variegatus).

Authors:  Alex Junior Souza de Souza; Andreza Pinheiro Malheiros; Victor Lopes da Silva; Tereza Cristina da Silva; Bruno Cogliati; Lilian Rose Marques de Sá
Journal:  Animals (Basel)       Date:  2022-07-28       Impact factor: 3.231

Review 7.  The Natural Course of Non-Alcoholic Fatty Liver Disease.

Authors:  Luis Calzadilla Bertot; Leon Anton Adams
Journal:  Int J Mol Sci       Date:  2016-05-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.